Reimbursement Decisions Logo
Guest | Login/Register
Your foremost guide to global pricing and reimbursement decisions.TM

Canadian Drug Review Reimbursement Decision


Back to Decisions Master Page
  VPRIV
Generic velaglucerase alfa
Company Shire Human Genetic Therapies
Indication Gaucher disease
Condition Endocrine, nutritional and metabolic diseases
Submission Type
Patient Population Velaglucerase alfa has a Health Canada indication as a long-term enzyme replacement therapy for pediatric and adult patients with GD1. It is available as a sterile lyophilized powder in single- use vials of 400 U per vial. The Health Canada-approved dose is 60 U/kg administered every other week as a 60-minute intravenous (IV) infusion.
Status Complete
Date of Recommendation 2011-04-25
Recommendation Summary List with criteria/condition
Recommendation Details The Canadian Expert Drug Advisory Committee (CEDAC) recommends that velaglucerase alfa be listed for patients with type 1 Gaucher Disease (GD1) in jurisdictions that provide funding for imiglucerase, when it is cost saving to do so.
Reason for Recommendation 1. In one small (N = 35) double-blind randomized controlled trial (RCT) of patients with GD1, velaglucerase alfa was reported to be non-inferior to imiglucerase, based on improvements in mean hemoglobin concentration. 2. Velaglucerase alfa is less costly compared with imiglucerase (subject to dose and patient weight). Of Note: 1. On a per unit (U) basis, velaglucerase alfa ($4.89/U) is less costly than imiglucerase ($6.15/U). However, given the potential for drug wastage and the availability of 200 U and 400 U vials of imiglucerase (compared with only 400 U vials of velaglucerase alfa), for some dose and weight combinations, imiglucerase may be less costly (e.g., pediatric patients who weigh less than 10 kg and who require doses of 45 U/kg to 60 U/kg). 2. The Committee noted that velaglucerase alfa is not an alternative for those patients in whom imiglucerase does not provide sufficient benefit.
Clinical Report:
Pharmacoeconomic Report:
Final Recommendation Report: CDR clinical report  CADTH-CDR Final Recommendation report

†The information referenced on this page is compiled from publicly available documents published by CADTH and is available through the embedded links.


Back to Decisions Master Page